NICE Rejects Novartis’ Afinitor, Citing Irrelevant Evidence And High Cost
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has rejected Novartis’ Afinitor for breast cancer, citing excessive cost and shooting down three out of four evidence submissions.